Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_5226_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Contents
- •Contributors
- •Extrinsic Factors
- •Intrinsic Factors
- •References
- •Indications
- •Surgical Technique
- •References
- •Background
- •Preoperative Considerations
- •Other Operative Points
- •Surgical Indications
- •Surgical Technique (Video 3.1)
- •Reported Outcomes
- •Potential Complications
- •References
- •4: Endoscopic Denker’s Approach
- •Background
- •Surgical Technique
- •Reported Outcomes
- •References
- •Background
- •Reported Outcomes
- •References
- •Background
- •Surgical Indications
- •Surgical Technique
- •Reported Outcomes
- •References
- •Background
- •Technical Factors
- •Patient Factors
- •Anatomic Factors
- •Imaging Review
- •Surgical Technique
- •Draf IIA
- •Draf IIB (Video 7.2)
- •References
- •Background
- •Surgical Techniques
- •Standard Frontal Sinus Approaches
- •Modified Hemi-Lothrop Procedure (Eloy IIC)
- •Modified Mini-Lothrop Procedure (Eloy IID)
- •Modified Subtotal-Lothrop Procedure (Eloy IIE)
- •Modified Central-Lothrop Procedure (Eloy IIF)
- •References
- •Background
- •Surgical Techniques
- •Modifications
- •Reported Outcomes
- •References
- •Background
- •Surgical Technique
- •References
- •11: The Outside-in Draf III Procedure
- •Background
- •Surgical Technique
- •Surgical Steps
- •Post-Operative Management
- •Reported Outcomes
- •Patient Reporting Outcome Measures
- •Operative Time
- •Complications
- •References
- •12: Balloon Sinuplasty
- •Background
- •Reported Outcomes
- •Surgical Technique
- •Local Anesthesia Protocol
- •Procedure: Maxillary Sinus Balloon Dilation
- •Procedure: Frontal Sinus Balloon Dilation
- •Procedure: Sphenoid Sinus Balloon Dilation
- •References
- •Background
- •Surgical Technique
- •Nasal Polypectomy
- •Maxillary Sinus Disease
- •Ethmoid Sinus Disease
- •Frontal Sinus Disease
- •Sphenoid Sinus Disease
- •Mucocele Drainage
- •Balloon Sinus Dilation
- •Outcomes
- •References
- •Background
- •Patient Selection
- •Room Setup/Equipment
- •Navigation Systems
- •Monitoring
- •Patient Comfort
- •Staff Training
- •Reported Outcomes/Evolving Practice Patterns
- •References
- •16: Steroid Eluting-Implants
- •Background
- •Indications
- •Background
- •Surgical Technique (Video 15.1)
- •In-Office Polypectomy
- •Reported Outcomes
- •References
- •Surgical Technique
- •Reported Outcomes
- •References
- •Background
- •Cryotherapy
- •Radiofrequency Ablation
- •Surgical Technique
- •Reported Outcomes
- •References
- •18: Inferior Turbinate Reduction
- •Background
- •Extramucosal Surgical Techniques
- •Complete Turbinectomy
- •Laser Cautery
- •Electrocautery
- •Cryotherapy
- •Turbinate Lateralization
- •Submucosal Techniques
- •Microdebrider Turbinoplasty (Video 18.1)
- •Coblation (Video 18.2)
- •Radiofrequency Ablation (Video 18.3)
- •Ultrasound Turbinoplasty
- •References
- •Background
- •Surgical Technique
- •Bioabsorbable Nasal Sidewall Implant (LATERA)
- •Patient Selection
- •Local Anesthesia
- •Surgical Technique
- •Patient Selection
- •Local Anesthesia
- •Surgical Technique
- •References
- •Background
- •Topical Antibacterial Therapy
- •Topical Antifungal Therapy
- •Senior Author’s Practice
- •Conclusions
- •References
- •21: Intravenous Antimicrobial Therapy
- •Background
- •When Is Recalcitrant Chronic Rhinosinusitis Infectious?
- •Anatomically Complicated Infections
- •Empiric Oral Antimicrobial Therapy
- •Oral Versus Intravenous Therapy
- •Staphylococcus
- •Streptococcus
- •Enterococcus
- •Enterobacterales
- •Pseudomonas
- •Other Gram-Negative Organisms
- •Anaerobes
- •Multidrug-Resistant Organisms
- •Antimicrobial Stewardship
- •References
- •Background
- •Chronic Rhinosinusitis
- •Glucocorticoids
- •Intranasal Steroid Irrigations
- •Rationale
- •Evidence
- •The Exhalation Delivery System
- •Rationale
- •Evidence
- •Steroid-Eluting Sinus Stents
- •Rationale
- •Rationale
- •Glucocorticoid Insensitivity
- •Conclusions
- •References
- •Background
- •Pathophysiology
- •Diagnosis
- •Aspirin Challenge
- •Aspirin Challenge Procedure
- •Aspirin Desensitization
- •Preparation
- •Logistics
- •Monitoring
- •Protocols
- •Aspirin-Induced Reactions
- •Maintenance Aspirin Therapy after Desensitization
- •Silent Desensitization
- •References
- •Background
- •Conclusions
- •References
- •Background
- •Patient Selection
- •Dupilumab
- •Omalizumab
- •Mepolizumab
- •Summary
- •References
- •Background
- •Povidone-Iodine (PVP-I) Rinses
- •Manuka Honey Rinses
- •Colloidal Silver
- •Topical Antibiotics
- •Photodynamic Therapy
- •Phage Therapy
- •Sinonasal Microbiota Transfer (SNMT)
- •Conclusion
- •References
- •Index

1 Introduction toRecalcitrant Chronic Rhinosinusitis
9
20. Boase S, Foreman A, Cleland E, Tan L, Melton-Kreft R, Pant H, Hu FZ, Ehrlich GD, Wormald
PJ. The microbiome of chronic rhinosinusitis: culture, molecular diagnostics and biolm
detection. BMC Infect Dis. 2013;
https://doi.org/10.1186/1471- 2334- 13- 210.
21. Bassiouni A, Paramasivan S, Shiffer A, Dillon MR, Cope EK, Cooksley C, Ramezanpour M,
Moraitis S, Ali MJ, Bleier BS, Callejas C, Cornet ME, Douglas RG, Dutra D, Georgalas C,
Harvey RJ, Hwang PH, Luong AU, Schlosser RJ, Tantilipikorn P, Tewk MA, Vreugde S,
Wormald PJ, Caporaso JG, Psaltis AJ.Microbiotyping the sinonasal microbiome. Front Cell
Infect Microbiol. 2020; https://doi.org/10.3389/fcimb.2020.00137.
22. Ramsey MM, Freire MO, Gabrilska RA, Rumbaugh KP, Lemon KP.Staphylococcus aureus
shifts toward commensalism in response to Corynebacterium species. Front Microbiol. 2016;
https://doi.org/10.3389/fmicb.2016.01230.
23. Hardy BL, Dickey SW, Plaut RD, Riggins DP, Stibitz S, Otto M, etal. Corynebacterium pseudodiphtheriticum exploits Staphylococcus aureus virulence components in a novel polymicrobial defense strategy. MBio. 2019;
https://doi.org/10.1128/mBio.02491- 18.
24. Kiryukhina NV, Melnikov VG, Suvorov AV, Morozova YA, Ilyin VK.Use of Corynebacterium
pseudodiphtheriticum for elimination of Staphylococcus aureus from the nasal cavity in
volunteers exposed to abnormal microclimate and altered gaseous environment. Probiotics
Antimicrob Proteins. 2013;
https://doi.org/10.1007/s12602- 013- 9147- x.
25. Paramasivan S, Bassiouni A, Shiffer A, Dillon MR, Cope EK, Cooksley C, etal. The international sinonasal microbiome study (ISMS): a multi-centre, multi-national characterization of
sinonasal bacterial ecology. Allergy. 2020; https://doi.org/10.1111/all.14276.
26. Antunes MB, Gudis DA, Cohen NA.Epithelium, cilia, and mucus: their importance in chronic
rhinosinusitis. Immunol Allergy Clin N Am. 2009; https://doi.org/10.1016/j.iac.2009.07.004.
27. Zuckerman JD, Lee WY, DelGaudio JM, Moore CE, Nava P, Nusrat A, Parkos
CA. Pathophysiology of nasal polyposis: the role of desmosomal junctions. Am J Rhinol.
2008; https://doi.org/10.2500/ajr.2008.22.3235.
28. Psaltis AJ, Bruhn MA, Ooi EH, Tan LW, Wormald PJ.Nasal mucosa expression of lactoferrin in patients with chronic rhinosinusitis. Laryngoscope. 2007; https://doi.org/10.1097/
MLG.0b013e31812e01ab.
29. Seshadri S, Lin DC, Rosati M, Carter RG, Norton JE, Suh L, Kato A, Chandra RK, Harris KE,
Chu HW, Peters AT, Tan BK, Conley DB, Grammer LC, Kern RC, Schleimer RP. Reduced
expression of antimicrobial PLUNC proteins in nasal polyp tissues of patients with chronic
rhinosinusitis. Allergy. 2012;
https://doi.org/10.1111/j.1398- 9995.2012.02848.x.
30. Ramanathan M Jr, Spannhake EW, Lane AP.Chronic rhinosinusitis with nasal polyps is associated with decreased expression of mucosal interleukin 22 receptor. Laryngoscope. 2007;
https://doi.org/10.1097/MLG.0b013e31811edd4f.
31. Hulse KE, Chaung K, Seshadri S, Suh L, Norton JE, Carter RG, Kern RC, Conley DB, Chandra
RK, Tan BK, Peters AT, Grammer LC 3rd, Harris KE, Torgerson TR, Kato A, Schleimer
RP. Suppressor of cytokine signaling 3 expression is diminished in sinonasal tissues from
patients with chronic rhinosinusitis with nasal polyps. J Allergy Clin Immunol. 2014; https://
doi.org/10.1016/j.jaci.2013.08.015.
32. Wentzel JL, Soler ZM, DeYoung K, Nguyen SA, Lohia S, Schlosser RJ.Leukotriene antagonists in nasal polyposis: a meta-analysis and systematic review. Am J Rhinol Allergy. 2013;
https://doi.org/10.2500/ajra.2013.27.3976.
33. Wang X, Zhang N, Bo M, Holtappels G, Zheng M, Lou H, Wang H, Zhang L, Bachert
C. Diversity of T
cytokine proles in patients with chronic rhinosinusitis: a multicenter
H
study in Europe, Asia, and Oceania. J Allergy Clin Immunol. 2016; https://doi.org/10.1016/j.
jaci.2016.05.041.
34. Wang ET, Zheng Y, Liu PF, Guo LJ.Eosinophilic chronic rhinosinusitis in East Asians. World
J Clin Cases. 2014; https://doi.org/10.12998/wjcc.v2.i12.873.
35. Yao Y, Yang C, Yi X, Xie S, Sun H.Comparative analysis of inammatory signature proles
in eosinophilic and noneosinophilic chronic rhinosinusitis with nasal polyposis. Biosci Rep.
2020; https://doi.org/10.1042/BSR20193101.

10
36. Mahdavinia M, Suh LA, Carter RG, Stevens WW, Norton JE, Kato A, Tan BK, Kern RC,
Conley DB, Chandra R, Lavin J, Peters AT, Grammer LC 3rd, Schleimer RP.Increased noneosinophilic nasal polyps in chronic rhinosinusitis in US second-generation Asians suggest
genetic regulation of eosinophilia. J Allergy Clin Immunol. 2015; https://doi.org/10.1016/j.
jaci.2014.08.031.
37. Katotomichelakis M, Tantilipikorn P, Holtappels G, De Ruyck N, Feng L, Van Zele T,
Muangsomboon S, Jareonchasri P, Bunnag C, Danielides V, Cuvelier CA, Hellings PW, Bachert
C, Zhang N.Inammatory patterns in upper airway disease in the same geographical area may
change over time. Am J Rhinol Allergy. 2013; https://doi.org/10.2500/ajra.2013.27.3922.
38. Kim SJ, Lee KH, Kim SW, Cho JS, Park YK, Shin SY. Changes in histological features of
nasal polyps in a Korean population over a 17-year period. Otolaryngol Head Neck Surg.
2013; https://doi.org/10.1177/0194599813495363.
39. Staudacher AG, Peters AT, Kato A, Stevens WW.Use of endotypes, phenotypes, and inammatory markers to guide treatment decisions in chronic rhinosinusitis. Ann Allergy Asthma
Immunol. 2020; https://doi.org/10.1016/j.anai.2020.01.013.
40. Tau G, Rothman P.Biologic functions of the IFN-gamma receptors. Allergy. 1999; https://doi.
org/10.1034/j.1398- 9995.1999.00099.x.
41. Valeri M, Raffatellu M.Cytokines IL-17 and IL-22in the host response to infection. Pathog
Dis. 2016; https://doi.org/10.1093/femspd/ftw111.
42. Junttila IS.Tuning the cytokine responses: an update on Interleukin (IL)-4 and IL-13 receptor
complexes. Front Immunol. 2018; https://doi.org/10.3389/mmu.2018.00888.
43. Kato A, Schleimer RP, Bleier BS.Mechanisms and pathogenesis of chronic rhinosinusitis. J
Allergy Clin Immunol. 2022; https://doi.org/10.1016/j.jaci.2022.02.016.
44. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, Förster-Ruhrmann U,
Kowalski ML, Olszewska-Ziąber A, Holtappels G, De Ruyck N, Wang X, Van Drunen C,
Mullol J, Hellings P, Hox V, Toskala E, Scadding G, Lund V, Zhang L, Fokkens W, Bachert
C.Inammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J
Allergy Clin Immunol. 2016; https://doi.org/10.1016/j.jaci.2015.12.1324.
45. Gevaert P, Omachi TA, Corren J, Mullol J, Han J, Lee SE, Kaufman D, Ligueros-Saylan M,
Howard M, Zhu R, Owen R, Wong K, Islam L, Bachert C.Efcacy and safety of omalizumab
in nasal polyposis: 2 randomized phase 3 trials. J Allergy Clin Immunol. 2021; https://doi.
org/10.1016/j.jaci.2020.05.032.
46. Bachert C, Sousa AR, Lund VJ, Scadding GK, Gevaert P, Nasser S, Durham SR, Cornet ME,
Kariyawasam HH, Gilbert J, Austin D, Maxwell AC, Marshall RP, Fokkens WJ.Reduced
need for surgery in severe nasal polyposis with mepolizumab: randomized trial. J Allergy Clin
Immunol. 2017; https://doi.org/10.1016/j.jaci.2017.05.044.
47. Bachert C, Han JK, Desrosiers M, Hellings PW, Amin N, Lee SE, Mullol J, Greos LS, Bosso
JV, Laidlaw TM, Cervin AU, Maspero JF, Hopkins C, Olze H, Canonica GW, Paggiaro P, Cho
SH, Fokkens WJ, Fujieda S, Zhang M, Lu X, Fan C, Draikiwicz S, Kamat SA, Khan A, Pirozzi
G, Patel N, Graham NMH, Ruddy M, Staudinger H, Weinreich D, Stahl N, Yancopoulos GD,
Mannent LP. Efcacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from
two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials.
Lancet. 2019;
48. Gurrola J 2nd, Borish L. Chronic rhinosinusitis: endotypes, biomarkers, and treatment
response. J Allergy Clin Immunol. 2017; https://doi.org/10.1016/j.jaci.2017.10.006.
49. Cardell LO, Stjärne P, Jonstam K, Bachert C.Endotypes of chronic rhinosinusitis: impact on
management. J Allergy Clin Immunol. 2020; https://doi.org/10.1016/j.jaci.2020.01.019.
https://doi.org/10.1016/S0140- 6736(19)31881- 1.
A. M. Choi and T. B. Locke

Part II
Surgical Procedures for Recalcitrant CRS

Revision Endoscopic Sinus Surgery:
Maxillary, Ethmoid, andSphenoid
JohnR.Craig
Key Points
• Revision endoscopic sinus surgery (ESS) should be considered in patientswith
objectively conrmed sinusitis whocontinue to suffer from sinonasalsymptoms
following prior ESSand appropriate medical therapy.
• Clinical features that may increase the risk of ESS failureshould be considered
when managing refractory chronic rhinosinusitis patients. These include nasal
polyps, asthma, frontal sinus disease, and a history of prior ESS.
• Certain maneuvers such as complete ethmoid dissection, middle turbinate resec-
tion, and septoplasty may lead to improved ESS outcomes and should be considered during revision ESS.
• When revision ESS is appropriately selected and performed for chronic rhinosi-
nusitis patients, it should lead to symptomatic improvements that areequivalent
to primary ESS.
2
Indications
The indications for revision endoscopic sinus surgery (ESS) are generally the same as
for primary ESS. After ESS, patients complaining of cardinal symptoms of CRS
(nasal obstruction, anterior and posterior nasal drainage, smell loss, facial pressure)
due to conrmed inammatory and/or infectious sinus diseaseon nasal endoscopy or
Supplementary Information The online version contains supplementary material available at
https://doi.org/10.1007/978- 3- 031- 89191- 5_2.
J. R. Craig (*)
Department of Otolaryngology-Head and Neck Surgery, Henry Ford Health,
Detroit, MI, USA
e-mail: Jcraig1@hfhs.org
© The Author(s), under exclusive license to Springer Nature
Switzerland AG 2025
J. T. Lee etal. (eds.), Advances in Surgical and Medical Interventions for
Recalcitrant Chronic Rhinosinusitis,
https://doi.org/10.1007/978-3-031-89191-5_2
13

14
imaging modalities should be offered revision ESS when they fail one or more courses
of appropriate medical management [1]. Revision ESS may also be necessary if
patients develop iatrogenic sinus disease from scarring like mucoceles, regardless of
symptoms.
Once patients meet criteria for revision ESS, surgeons must determine why the
previous ESS failed, and which sinuses require revision surgery to alleviate patients’
symptoms or prevent future complications from scarringof the sinonasal cavities.
The next sections will discuss reported outcomes of primary and revision ESS, as
well as patient-related and technical reasons for ESS failures. These reasons for
ESS failure will then be considered when performing revision ESS.
J. R. Craig
Outcomes ofPrimary andRevision ESS
Most published ESS success rates relate to primary ESS. Multiple studies have
shown improvement in cardinal sinusitis symptoms following ESS in 90–100% of
chronic rhinosinusitis (CRS) cases, [2, 3] recurrent acute rhinosinusitis, [4] odontogenic sinusitis when the dental infectious source is controlled, [5] and paranasal
sinus fungal balls [6]. Most literature on long-term ESS failure rates pertains to
chronic rhinosinusitis with or without nasal polyps (CRSwNP, CRSsNP), with
4–19% of primary cases requiring revision ESS [7–10]. When necessary for CRS,
revision ESS is performed on average about 2–5years after primary ESS, but time
to revision is shorter for patients with CRSwNP [8, 11–13]. There have been fewer
publications on revision ESS outcomes, but studies to date have demonstrated similar degrees of symptomatic improvement in CRS patients when comparing primary
to revision ESS [14–16]. Also important, a study based on all-payer claims databases showed equivalent rates of major complications after revision ESS (0.46%)
compared to primary ESS (0.36%) [17]. However, some minor complications may
be more common after revision ESS, like synechiae [18].
Risk Factors forESS Failure
Multiple studies have demonstrated various patient-related and technical (surgical)
factors that may place patients at risk for requiring revision ESS.One of the most
frequently cited patient-related factors that contributes to revision ESS is CRSwNP,
[8, 9]. Revision rates also increase in the setting of tissue eosinophilia, [19], eosinophilic mucin, [20] and aspirin sensitivity [13]. Additionally, allergic rhinitis [9, 21]
and asthma [11] independently increase the risk of revision ESS for CRS. Other
reported risk factors for revision ESS include female gender, [8, 9] older age [9],
smoking, [12] frontal sinus disease, [9, 13] prior revision ESS, [9] bacterial biolms,
[1, 22, 23] immunodeciency, [7, 24] cystic brosis, [25] and granulomatosis with
polyangiitis [7]. Another possible source of ESS failure is odontogenic sinusitis when
the infectious dental source is either overlooked or inadequately treated [5, 26, 27].
Regarding technical factors, multiple studies have shown that certain computed tomography (CT) or endoscopic ndings are common in patients

2 Revision Endoscopic Sinus Surgery: Maxillary, Ethmoid, andSphenoid
15
undergoing revision ESS, and presumably these anatomic or pathologic ndings
contributed to the ESS failures. Common CT and endoscopic ndings in patients
undergoing revision ESS include residual ethmoid sinus partitions (50–96%),
osteitis or neo- osteogenesis (66%), nasal polyps (20–60%), synechiae (20–56%)
(Fig.2.1), middle turbinate (MT) scarring/lateralization (8–78%) (Fig.2.2), resid-
ual uncinate plus maxillary recirculation (4–52%) (Fig.2.3), and maxillary, sphenoid, or frontal sinus stenosis (15–48%) [28–33]. While it is reasonable to presume
these ndings contribute to ESS failures, future studies should correlate these
ndings with sinonasal symptoms to understand which ndings are most important to address with revision ESS.
Two features that have been associated with worse symptomatic outcomes after
ESS include synechiae and osteitis. Sinus synechiae can occur anywhere in the
sinonasal cavities after ESS.The location and extent of synechiae may be a factor
in the severity of persistent symptoms after ESS and the need for subsequent revision ESS [18]. Another common nding in CRS patients who have had prior ESS is
osteitis (neo-osteogenesis) of sinus walls or partitions, [34–36] especially in the
ethmoid sinus [37]. Osteitis has been correlated with worsened objective measures
of disease severity on CT, endoscopy, and olfactory scores, [38] and may worsen
postoperative outcomes after ESS [34, 39]. One literature review concluded that
osteitic bone should be removed during ESS when feasible, [38] but more research
is necessary to determine the prognostic signicance and optimal management of
osteitis in CRS.
Fig. 2.1 Endoscopic view
of right-sided sinus cavities
after prior endoscopic
sinus surgery,
demonstrating multiple
synechiae (yellow
asterisks), and thick mucus
that may be related to
possible recirculation or
stenotic ostia (yellow
arrows). LP lamina
papyracea, ST superior
turbinate, NS nasal septum

16
Fig. 2.2 Endoscopic view
of left-sided sinus cavities
after prior endoscopic
sinus surgery,
demonstrating a partially
resected middle turbinate
(MT) with the superior
portion having scarred to
the lamina papyracea (LP)
(yellow arrow). Scarring in
this region can cause
frontal sinus outow
obstruction and either
frontal sinusitis or
mucocele. NS nasal septum
Fig. 2.3 Endoscopic view
of prior right-sided
endoscopic maxillary
antrostomy, with evidence
of recirculation due to
either incomplete
dissection of the anterior
aspect of the antrostomy
leaving residual uncinate
tissue, or scarring in this
region after complete
antrostomy (yellow
asterisk). Mucopurulence
is seen draining from the
natural ostium (yellow
arrow)back into the
maxillary sinus (MS), and
posteriorly through the
middle meatus into the
nasopharynx
J. R. Craig
Surgical Techniques toAddress Risk Factors forESS Failure
Multiple studies have demonstrated that certain surgical techniques improve symptomatic results and prolong time to revision ESS.These studies have generally been
conducted in the setting of primary ESS for CRS, but this data will be extrapolated
to revision ESS for this chapter.

ab
2 Revision Endoscopic Sinus Surgery: Maxillary, Ethmoid, andSphenoid
17
In patients with CRSwNP, one of the most common conditions requiring revision
ESS, the decision to perform more extensive ESS results in decreased polyp recurrence rates, lower revision ESS rates, and longer times to revision ESS when compared to the conventional functional ESS. Extensive ESS refers to wide openings
being created into each sinus with complete removal of ethmoid sinus and frontal
recess partitions with middle turbinate resection (MTR) [40–43]. The end result is
creating a common cavity between all the sinus cavities to improve topical saline
and drug delivery, disease monitoring, and sinus debridements (Fig. 2.4) [1].
Surgeons should consider more extensive ESS in CRSwNP patients for both primary and revision cases. It remains to be studied whether extensive ESS is more
effective during revision ESS in conditions other than CRS, but may be necessary in
some cases if it can be performed safely.
Middle turbinate resection (MTR) is a frequent point of debate during ESS.Partial
and subtotal MTR during ESS for CRSwNP have been shown to be safe, with
extremely low rates of postoperative epistaxis, frontal sinus stenosis, cerebrospinal
uid leaks, empty nose syndrome, and hyposmia/anosmia [44–48]. While there is
mixed evidence in the literature with regard to efcacy of MTR during ESS for
CRSwNP, multiple studies have shown a preponderance of benet with improved
sinonasal quality-of-life (QOL) [43], olfaction, [41, 48, 49] sinus topical irrigation
delivery, [50] decreased polyp recurrence, [21, 40–42] decreased need for revision
ESS, [40, 42, 43] and longer times to revision ESS [12, 43]. Conversely, some studies have shown no signicant differences in QOL improvements with MTR versus
MT preservation during primary ESS for CRS [49, 51, 52]. Interestingly, Scangas,
Fig. 2.4 Endoscopic view of sinus cavities a, immediately, and b, 6months postoperatively after
extensive right-sided endoscopic sinus surgery. The maxillary (MS), ethmoid, and sphenoid
sinuses (SS) appear to communicate as a common cavity, after wide maxillary antrostomy and
sphenoidotomy, and removing all ethmoid partitions between the superior turbinate (ST) and lamina papyracea (LP), and superiorly to the fovea ethmoidalis (FE). The middle turbinate was subtotally resected, with a small remnant left superiorly along the cribriform plate (not seen in b with
the 0° view)

18
J. R. Craig
etal. showed that while bilateral MTR did not improve QOL after primary ESS, it
did improve sinonasal QOL after revision ESS [52]. Given the high prevalence of
MT scarring and lateralization at the time of revision ESS for CRS, and improved
outcomes after primary and revision ESS for CRSwNP, there is good reason to perform MTR at the time of revision ESS for CRS, especially for CRswNP.
There are also some considerations that have mixed evidence to date, but may
improve surgical outcomes. Should patients undergo septoplasty during ESS? A
recent matched case-control study showed that in patients undergoing revision ESS,
having an untreated deviated nasal septum was an independent predictor of worsened disease severity, and therefore could contribute to ESS failures [53]. While
some studies have shown no signicant differences in QOL in patients getting ESS
versus ESS plus septoplasty, [54] more studies have shown reductions in revision
ESS when septoplasty is performed with ESS [55, 56]. The recent international
consensus statement on rhinosinusitis recommended concurrent septoplasty during
ESS whenthe septum is notably deviated, given a preponderance of published literature demonstrating improved nasal obstruction, improved ESS access (Fig.2.5),
and possibly a reduced need for revision ESS [1].
Another consideration during revision ESS is whether inferior turbinate reduction (ITR) should be performed. Soudry, etal. conducted a multi-center prospective
cohort study of patients undergoing primary or revision ESS with or without bilateral ITR. While ITR did not result in differences in overall QOL metrics, it did lead
to improved nasal obstruction scores [57]. In summary, if patients have prominent
nasal obstruction and clinically evident septal deviation or inferior turbinate
Fig. 2.5 Endoscopic views of the right nasal cavity during revision endoscopic sinus surgery,
demonstrating the improvement in medial-to-lateral dimension between the nasal septum (NS) (a)
and the lateral nasal wall after endoscopic septoplasty (b). This greatly improved surgical access
to the ethmoid sinus and frontal recess regions. Additionally, this improved the patient’s nasal
airow on this side

2 Revision Endoscopic Sinus Surgery: Maxillary, Ethmoid, andSphenoid
19
hypertrophy, septoplasty and/or ITR may provide additional benet when performed with ESS.Regardless of symptoms, these techniques may improve intraoperative access for sinus dissection, and postoperative access for sinus disease
monitoring and debridements.
One nal point to discuss is the use of image-guided surgery, which has become
commonly used by many surgeons during ESS.While evidence has been mixed
with regard to whether image-guided surgery improves outcomes and decreases
complications, the recent international consensus on rhinosinusitis presented multiple studies showing its benets, especially in advanced or revision ESS, and recommended it as a viable option during ESS [1].
Surgical Technique
All patients should undergo preoperative CT evaluation to identify anatomic reasons for persistent disease, locations of persistent disease, and anatomy that may be
high-risk for complications and for surgical failure intra-operatively [58]. Specic
attention should be paid to anatomy that can contribute to persistent disease or limit
access to all sinuses and ostia, areas of residual bony partitions with or without
osteitis/neo-osteogenesis, lateralization of middle turbinates, and deviated nasal
septum. High-risk anatomy to consider includes orbital and/or skull base dehiscences, high maxillary:ethmoid high ratio, low-lying anterior ethmoid arteries,
dehiscences of the optic nerve or carotid artery, and the presence of Onodi(sphenoethmoid) cells.
Intra-operatively, the head of the bedshould be elevated, either by placing the
patient in reverse Trendelenburg or placing the patient in a head-up exed position
to approximately 20° from the horizontal, to improve hemostasis during the case
[59]. Decongesting the nasal cavities should be performed early and can be performed with either topical epinephrine 1:1000, oxymetazoline, or cocaine on nasal
pledgets. Once adequate time has been allowed for nasal decongestion, approximately 5–10min, nasal endoscopy is performed. The goals of this initial endoscopy
are to assess for areas of obstructionor previous treatment failure. First, surgeons
shouldassessthe septum and inferior turbinates; if they are preventing access to the
middle meatus, sphenoethmoid recess, or frontal recess,surgeons should consider
septoplasty +/− inferior turbinate outfracture or reduction. Next, the sinus drainage
pathways should be assessed for areas of current disease, specically for scarring, purulence, edema, or polyps. If purulence is present, cultures should be
obtained for targeted antibiotics in the perioperative period.
The middle turbinate should alsobe assessed. Surgeons should consider MTR
for CRSwNP, or in other cases where the MT is felt to be high risk for scarring and
lateralization. MTR can be performedprior to opening sinuses to improve surgical
access, leaving a remnant superiorly as a landmark for the medial extent of ethmoidectomy and for identifying skull base. Alternatively, MTR can be performed after
nishing ESS, if surgeons prefer to leave the MT completely intactas landmark
during surgery.If septoplasty is necessary for surgical access to the sinuses, it can
Соседние файлы в папке Библиотека им академика М.И. Перельмана
